In this article
OrderlyMeds advertises a two-month starter package separately from continuing treatment. The lowest advertised average is therefore not automatically the right baseline for someone already taking a GLP-1 medicine.
This guide compares other package structures and recurring-care models with that distinction in view. It gives particular attention to transfer eligibility, the first post-starter refill, and the clinical support included after enrollment.
Compare the next clinically appropriate treatment period, not a starter package you may not qualify to use. CoreAge Rx holds the first sponsored position; that does not establish that it best meets every criterion.
What to know first
- Compare the next clinically appropriate treatment period, not a starter package you may not qualify to use.
- CoreAge Rx is the first listing through a disclosed commercial arrangement.
- Confirm the proposed product, care arrangement, and complete written payment terms.
How this shortlist was selected
CoreAge Rx is number one because it is our featured commercial partner. That position is predetermined by our commercial relationship, and we may earn compensation through its links. Other entries illustrate relevant care and payment models; their order is not a ranking of medication quality, safety, or patient outcomes.
Compare the next clinically appropriate treatment period, not a starter package you may not qualify to use. We used the provider documents linked beside each entry, checked September 21, 2026. We did not purchase treatment, test private accounts, audit every license, or measure response times. The product and current written quote for your own care still need confirmation. Read our review method.
01. CoreAge Rx — featured partner
Our first sponsored comparison offers a self-pay assessment. Ask whether the displayed plan applies to a transfer and request the full charge for the proposed prescription.
The current sale page advertises semaglutide from $99 per month and tirzepatide from $149 per month, with no membership fee. Those are advertised starting figures, not a personalized checkout quote. The plan length and total amount due must be read alongside the monthly equivalent.
The sale page says CoreAge works with U.S. compounding pharmacies and describes 503A facilities. A category of pharmacy is not a substitute for the name, address, and state license of the pharmacy filling your own prescription. Request that information before deciding.
Continue with our CoreAge Rx review and pricing details.
02. Fifty 410
A package-based comparison with separate tirzepatide tiers. The correct tier and transfer eligibility determine which total belongs in the comparison.
Fifty 410 lists a three-month compounded tirzepatide starter package at $399 total, displayed as $133 per month. The listed mid- and higher-dose packages are $499 and $549 total. Its semaglutide monthly option is $199. These are different products and package sizes.
Ask which package matches the proposed prescription and whether a returning patient qualifies for a starter offer. A three-month supply and monthly billing are separate arrangements.
Check the official Fifty 410 program page for the current offer and conditions. Our Fifty 410 alternatives comparison examines other care models.
03. Big Easy Weight Loss
Uses 12-week packages with starter discounts and pharmacy choices. Match the treatment period and confirm whether an existing patient qualifies for the promotion.
Big Easy shows 12-week starting packages for compounded semaglutide and tirzepatide. Its page displays starter discounts alongside regular figures: $399 versus $495 for semaglutide, and $499 versus $599 for tirzepatide. Confirm the eligible package and pharmacy before relying on a displayed price.
Twelve weeks is 84 days, not three calendar months. Compare the exact quantity, pharmacy, ingredients, and whether the new-patient discount applies to a transfer.
Check the official Big Easy Weight Loss program page for the current offer and conditions. Our Big Easy Weight Loss alternatives comparison examines other care models.
04. GobyMeds
Publishes three-month starter bundles with explicit totals. These remain starter offers rather than automatic maintenance quotes.
GobyMeds lists a three-month semaglutide starter bundle at $299 total and a tirzepatide starter bundle at $399 total. Its $99 and $133 monthly headlines describe those bundles; the page says the lowest figures can reflect multi-month or introductory offers.
Cancellation depends on whether the prescription has reached the pharmacy. A prepaid starter bundle is not a guarantee of the same renewal price, and HSA/FSA payment is not insurance coverage.
Check the official GobyMeds program page for the current offer and conditions.
05. NiceRx
Separates first-month and ongoing prices. Its continuing rate is useful when you want to compare costs after introductory treatment.
NiceRx lists semaglutide at $99 for the first month, then $199 per month, and tirzepatide at $199 for the first month, then $299. It says medication, provider access, and shipping are included.
Budget with the ongoing price, not just the first month. The page directs cancellation requests to email and says dispensed medication cannot be returned; confirm the order stage and next renewal separately.
Check the official NiceRx program page for the current offer and conditions. Our NiceRx alternatives comparison examines other care models.
06. Mochi Health
A different model using membership plus dose-based medication charges. Compare the combined recurring total and care access instead of only the drug advertisement.
Mochi advertises a $39 first membership month for eligible new subscribers and a $79 ongoing monthly membership. Its August 2026 pricing explanation describes dose-based compounded semaglutide prices of $60–$99 and tirzepatide prices of $90–$199, with medication billed separately.
Mochi’s pricing article says its transition to dose-based prices did not change the pharmacies or additives for the plans discussed. It does not identify your personal dispensing pharmacy. Confirm the pharmacy and complete formulation shown in your own care plan.
Continue with our Mochi Health review and pricing details.
The current OrderlyMeds baseline
The pricing page advertises a two-month starter package at $149 total for compounded semaglutide and $299 total for compounded tirzepatide. Those totals correspond to $74.50 and $149.50 per month, even though the display rounds the monthly headlines. The offer is labeled for new customers.
OrderlyMeds’ current pricing page distinguishes a new-customer starter program from continuing treatment and branded plans. It describes online screening, provider contact, pharmacy shipping, and follow-up support.
OrderlyMeds describes text-based provider review and pharmacy preparation after approval. Its stated shipping time is an estimate and should not be confused with guaranteed prescribing or a tested turnaround time.
The details that decide this comparison
The listed starter totals are $149 for two months of semaglutide and $299 for two months of tirzepatide. Confirm the starter criteria rather than applying those averages to all ongoing care.
Ask for the first post-starter charge, prescribed quantity, and any dose-related change. A discount at enrollment does not establish a fixed maintenance price.
Separate provider contact, nutrition resources, community features, and any third-party benefits. Ask which services continue with the selected plan.
Keep the treatment distinction clear
An FDA-approved branded medicine and a compounded preparation have different regulatory status. Compounded drugs are not FDA-approved. Trials of an approved product do not prove that every compounded version has the same performance.
Ask the prescribing professional why the exact product is appropriate for you, and identify the dispensing pharmacy. A price, a website’s appearance, or a place in this list cannot establish personal suitability. Our guide to compounded drugs and FDA approval explains the distinction.
Before you make a change
Before transferring, ask both services to distinguish enrollment eligibility from clinical eligibility for the advertised starter prescription. Those decisions are related but not identical.
Use your current label and treatment history when requesting a quote. A new provider should assess the appropriate continuation rather than fit your care to its cheapest package.
Sources & research notes
Checked September 21, 2026. Provider pages document the provider’s own statements; they do not independently establish treatment safety or results. This is desk research, not a product test or clinical review.
- CoreAge Rx: official treatment overviewProvider-published information · Checked September 21, 2026
- CoreAge Rx: current sale offerProvider-published information · Checked September 21, 2026
- CoreAge Rx: plan billing explainedProvider-published information · Checked September 21, 2026
- CoreAge Rx: contact and professional-entity disclosuresProvider-published information · Checked September 21, 2026
- CoreAge Rx: purchasing processProvider-published information · Checked September 21, 2026
- Fifty 410: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- Big Easy Weight Loss: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- GobyMeds: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- NiceRx: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- Online Medical Weight Loss Program | Mochi HealthProvider-published information · Checked September 21, 2026
- Mochi: August 2026 dose-based pricingProvider-published information · Checked September 21, 2026
- Contact us | Mochi HealthProvider-published information · Checked September 21, 2026
- No Insurance GLP-1 and GLP-1/GIP Medication Cost CalculatorProvider-published information · Checked September 21, 2026
- FDA: concerns with unapproved GLP-1 drugsRegulatory / public agency · Checked September 21, 2026
- FDA: risks of compounded drugsRegulatory / public agency · Checked September 21, 2026
Read our methodology · Commercial disclosure · Request a correction